Business Wire

MERZ-THERAPEUTICS

Share
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The completion of this deal, valued at USD 185 million in cash, bolsters Merz Therapeutics’ market position by enhancing offerings for people living with Parkinson’s disease and expanding into the multiple sclerosis (MS) space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240710459851/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“The addition of INBRIJA and (F)AMPYRA to the treatment portfolio underlines Merz Therapeutics’ global Pivot for Growth strategy to both evolve the current portfolio and achieve critical scale and global reach,” said Stefan König, CEO of Merz Therapeutics. “Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment. This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders.”

INBRIJA and (F)AMPYRA are projected to immediately add topline revenue which will enhance Merz Therapeutics’ ability to accelerate clinical development of its existing and new assets. Its U.S. business is forecasted to contribute more than 75% of INBRIJA’s and (F)AMPYRA’s total global revenues over the next 10 years. Additionally, the company expects the U.S. workforce to increase by more than 50%.

INBRIJA is a significant advancement for people living with Parkinson's disease as it provides an on-demand, inhalable form of levodopa, offering an effective way to manage “OFF” episodes. This method of delivery, achievable through the innovative and proprietary technology platform, ARCUS®, is especially valuable for people who need rapid relief from their symptoms, which cannot be achieved reliably through oral intake.

(F)AMPYRA is the first medication approved for improving walking in patients with MS, demonstrated by an improved walking ability.

“Expanding the portfolio with INBRIJA, including plans for worldwide product roll-out, and (F)AMPYRA allows Merz Therapeutics the opportunity to leverage its experience in the specialty neurology space to serve even more patients living with neurological disorders and support the physicians who treat them,” said Stefan Albrecht, Chief Scientific and Medical Officer. “Because these treatments complement the company’s product portfolio and distribution system, we are well positioned to support patients who depend on these products seamlessly.”

About INBRIJA

INBRIJA® is an inhaled prescription levodopa medicine used to treat the return of Parkinson’s symptoms (known as “OFF” episodes) in people with Parkinson’s disease who are treated with carbidopa/levodopa medicines. It does not replace the regular carbidopa/levodopa medicines. INBRIJA is not to be used by people with Parkinson’s disease who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks. The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea and change in the color of saliva or spit.

About FAMPYRA

FAMPYRA® is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). FAMPYRA is indicated in the European Union for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 4-7). In clinical trials, the highest incidence of adverse reactions identified with FAMPYRA given at the recommended dose was urinary tract infection. Other adverse drug reactions identified were mainly divided between neurological disorders such as insomnia, balance disorder, dizziness, paraesthesia and headache, and gastrointestinal disorders including nausea, dyspepsia and constipation. In post-marketing experience, there have been reports of seizure. Please see FAMPYRA EPAR for more information.

About AMPYRA

AMPYRA® is an extended-release tablet formulation of dalfampridine (4-aminopyridine, 4-AP or fampridine). AMPYRA is a potassium channel blocker approved as a treatment to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat. Please see the AMPYRA Patient Medication Guide for more information.

About Merz Therapeutics

Merz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.

Please visit www.merztherapeutics.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710459851/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europastry and Blue Yonder Team Up To Strategically Drive Efficiency, Sustainability and Customer Satisfaction15.1.2025 10:00:00 CET | Press release

Global bakery leader implements Blue Yonder transportation management solutions supported by BlueGistics to optimize supply chain operations across Europe Delivering frozen bakery products presents several challenges that can impact the efficiency, profitability and sustainability of the supply chain. To address these challenges, Europastry, a world leader in the frozen bakery industry, has selected Blue Yonder’s transportation management solutions to evolve its supply processes and optimize its logistics operations. The transformational project was deployed by BlueGistics, a Blue Yonder partner and worldwide consulting company specializing in the implementation of Transportation Management Systems. With an ever-growing distribution network spanning more than 80 countries, Europastry sought to increase efficiency in its transportation processes, reduce costs, and continue delivering its wide range of bakery products efficiently. Blue Yonder’s transportation management solutions provide

Tax Systems Launches AI-powered, SaaS Solution for Global Pillar Two Compliance and Reporting15.1.2025 09:00:00 CET | Press release

Secure, scalable software that ensures organisations are prepared for the challenges of OECD Pillar Two rules now and in the future Tax Systems, the global multi-tax compliance SaaS provider, has today announced the availability of Pillar2, an intuitive solution to de-risk and simplify compliance with the OECD’s global Pillar Two tax rules. Designed for organisations operating across multiple jurisdictions - Pillar2 will save businesses valuable time and reduce the risk of errors, so they can cost effectively operationalise Pillar Two reporting and comply with confidence. Pillar2 integrates seamlessly with the provisioning and country-by-country reporting applications on TaxSuite - Tax Systems’ modular platform for international tax compliance. This means organisations can upload information once and re-use it as a single source of truth for their tax compliance data - helping to ensure consistency and accuracy across the tax reporting cycle and strengthen tax control frameworks. The s

Regula Launches Full Support for Digital Travel Credentials in Latest Software Update15.1.2025 08:00:00 CET | Press release

Regula, a global developer of forensic devices and identity verification solutions, has updated its Regula Document Reader SDK. Now, the software fully supports the new Digital Travel Credential (DTC) format, aligned with the International Civil Aviation Organization (ICAO) standards. This enhancement enables governments, airlines, and border control authorities worldwide to process travel documents with unmatched security, efficiency, and ease—whether on-site or remotely. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115990355/en/ With Regula Document Reader SDK, travelers can create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document like ePassport. (Graphic: Regula) The DTC is a secure digital solution that streamlines travel experiences. It consolidates key personal information into a single virtual document that travelers can store on their mobile dev

Cargill Puts Bold Innovation at Center of Effort to Decarbonize Shipping15.1.2025 08:00:00 CET | Press release

Continued investment in wind assisted propulsion, next-generation fuels and digital solutions key to moving the world’s goods more sustainably Cargill is advancing a new era in sustainable shipping, putting innovation and collaboration at the core of its mission to move goods responsibly across the globe. Through wind-assisted propulsion technologies, dual-fuel methanol-powered vessels, and digital solutions, Cargill is setting the standard for helping the industry advance progress toward the International Maritime Organization’s (IMO) 2050 net-zero target. Combining technical expertise with a commitment to industry-wide partnerships, Cargill is helping to future-proof the maritime sector while enabling customers to meet their sustainability goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114753261/en/ “Decarbonizing shipping is a monumental task that requires courage, innovation, and collaboration,” said Jan Dielem

Bureau Veritas: Statement15.1.2025 07:34:00 CET | Press release

Following recent media commentary, Bureau Veritas indicates that it is in discussions with SGS regarding a potential business combination. There can be no assurance that these discussions will result in a transaction or other agreement. Bureau Veritas will not comment further and will only communicate in due course, if and when applicable. About Bureau Veritas Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye